(Q37932521)

25 August 2017

1 reference

title

Confronting the barriers to develop novel vaccines against brucellosis (English)

1 reference

25 August 2017

0 references

Juliana Cassataro

3

0 references

author name string

Sérgio Costa Oliveira

series ordinal

1

1 reference

25 August 2017

Guillermo Hernán Giambartolomei

series ordinal

2

1 reference

25 August 2017

publication date

1 September 2011

1 reference

Expert Review of Vaccines

25 August 2017

published in

1 reference

25 August 2017

volume

10

1 reference

25 August 2017

issue

9

1 reference

25 August 2017

page(s)

1291-1305

1 reference

Pathogenesis of bovine brucellosis.

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Biological properties of RB51; a stable rough strain of Brucella abortus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Genetic bases of the rifampin resistance phenotype in Brucella spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Rough vaccines in animal brucellosis: structural and genetic basis and present status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

The innate immune response against Brucella in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Immunity and protection against Brucella abortus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Recognition of microorganisms and activation of the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Role of Toll-like receptor 4 in induction of cell-mediated immunity and resistance to Brucella abortus infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

MyD88, but not toll-like receptors 4 and 2, is required for efficient clearance of Brucella abortus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

CD8+ Type 1 CD44hi CD45 RBlo T lymphocytes control intracellular Brucella abortus infection as demonstrated in major histocompatibility complex class I‐ and class II‐deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

The role of T cell subsets and cytokines in the regulation of intracellular bacterial infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Interferon-gamma is crucial for surviving a Brucella abortus infection in both resistant C57BL/6 and susceptible BALB/c mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Brucella abortus uses a stealthy strategy to avoid activation of the innate immune system during the onset of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

The sheathed flagellum of Brucella melitensis is involved in persistence in a murine model of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Evasion of Toll-like receptor 5 by flagellated bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Brucella abortus induces Irgm3 and Irga6 expression via type-I IFN by a MyD88-dependent pathway, without the requirement of TLR2, TLR4, TLR5 and TLR9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Brucella spp noncanonical LPS: structure, biosynthesis, and interaction with host immune system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Brucella lipopolysaccharide acts as a virulence factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

The differential interaction of Brucella and ochrobactrum with innate immunity reveals traits related to the evolution of stealthy pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Evidence of Brucella abortus OPS dictating uptake and restricting NF-kappaB activation in murine macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Brucella abortus inhibits major histocompatibility complex class II expression and antigen processing through interleukin-6 secretion via Toll-like receptor 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Role of the Brucella suis lipopolysaccharide O antigen in phagosomal genesis and in inhibition of phagosome-lysosome fusion in murine macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Brucella evades macrophage killing via VirB-dependent sustained interactions with the endoplasmic reticulum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Brucella: a Mr "Hide" converted into Dr Jekyll

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Subversion of Toll-like receptor signaling by a unique family of bacterial Toll/interleukin-1 receptor domain-containing proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Brucella TIR Domain-containing Protein Mimics Properties of the Toll-like Receptor Adaptor Protein TIRAP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Brucella control of dendritic cell maturation is dependent on the TIR-containing protein Btp1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Subversion of innate immune responses by Brucella through the targeted degradation of the TLR signaling adapter, MAL

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Immunological concepts of vaccine adjuvant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Vaccine adjuvant: it makes the difference

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

New horizons in adjuvants for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Liposomised recombinant ribosomal L7/L12 protein protects BALB/c mice against Brucella abortus 544 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Escheriosome-mediated delivery of recombinant ribosomal L7/L12 protein confers protection against murine brucellosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Immunization of mice with recombinant S-adenosyl-L-homocysteine hydrolase protein confers protection against Brucella melitensis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Brucella lumazine synthase elicits a mixed Th1-Th2 immune response and reduces infection in mice challenged with Brucella abortus 544 independently of the adjuvant formulation used

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

High order quaternary arrangement confers increased structural stability to Brucella sp. lumazine synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

A DNA vaccine encoding lumazine synthase from Brucella abortus induces protective immunity in BALB/c mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Adjuvants designed for veterinary and human vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

21 January 2018

The science of adjuvants

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Immunopotentiation of live brucellosis vaccine by adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Protection of mice against Brucella abortus 544 challenge by vaccination with recombinant OMP28 adjuvanted with CpG oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Immunogenicity of the Brucella melitensis recombinant ribosome recycling factor-homologous protein and its cDNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Mice immune responses to Brucella abortus heat shock proteins. Use of baculovirus recombinant-expressing whole insect cells, purified Brucella abortus recombinant proteins, and a vaccinia virus recombinant as immunogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Native-like, long synthetic peptides as components of sub-unit vaccines: practical and theoretical considerations for their use in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Modulation of immune responses in Balb/c mice vaccinated with Brucella abortus Cu-Zn superoxide dismutase synthetic peptide vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Minor nucleotide substitutions in the omp31 gene of Brucella ovis result in antigenic differences in the major outer membrane protein that it encodes compared to those of the other Brucella species

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Engineering of a polymeric bacterial protein as a scaffold for the multiple display of peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

A bile salt hydrolase of Brucella abortus contributes to the establishment of a successful infection through the oral route in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Mucosal immunity and vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

An oral vaccine based on U-Omp19 induces protection against B. abortus mucosal challenge by inducing an adaptive IL-17 immune response in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Improving vaccine performance with adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Vaccine antigen production in transgenic plants: strategies, gene constructs and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Challenges in mucosal vaccination of cattle

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Gene vaccination: plasmid DNA is more than just a blueprint

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

DNA vaccines: a key for inducing long-term cellular immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Induction of immune response in BALB/c mice with a DNA vaccine encoding bacterioferritin or P39 of Brucella spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Protective immunity induced by DNA-library immunization against an intracellular bacterial infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Enhanced efficacy of DNA vaccines against an intracellular bacterial pathogen by genetic adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

A DNA vaccine encoding Cu,Zn superoxide dismutase of Brucella abortus induces protective immunity in BALB/c mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Intraspleen delivery of a DNA vaccine coding for superoxide dismutase (SOD) of Brucella abortus induces SOD-specific CD4+ and CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Brucellosis vaccines: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

A combined DNA vaccine enhances protective immunity against Mycobacterium tuberculosis and Brucella abortus in the presence of an IL-12 expression vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

A combined DNA vaccine encoding BCSP31, SOD, and L7/L12 confers high protection against Brucella abortus 2308 by inducing specific CTL responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

An IL-15 adjuvant enhances the efficacy of a combined DNA vaccine against Brucella by increasing the CD8+ cytotoxic T cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Towards a Brucella vaccine for humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Evaluation of Brucella abortus DNA vaccine by expression of Cu-Zn superoxide dismutase antigen fused to IL-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Escheriosomes entrapped DNA vaccine co-expressing Cu-Zn superoxide dismutase and IL-18 confers protection against Brucella abortus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

The prime-boost strategy: exciting prospects for improved vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Jump-starting the immune system: prime-boosting comes of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Improved immunogenicity of a vaccination regimen combining a DNA vaccine encoding Brucella melitensis outer membrane protein 31 (Omp31) and recombinant Omp31 boosting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Protective immunity elicited by a divalent DNA vaccine encoding both the L7/L12 and Omp16 genes of Brucella abortus in BALB/c mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

DNA vaccines: immunology, application, and optimization*

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

DNA vaccines for targeting bacterial infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

DNA vaccines: ready for prime time?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Rough mutants defective in core and O-polysaccharide synthesis and export induce antibodies reacting in an indirect ELISA with smooth lipopolysaccharide and are less effective than Rev 1 vaccine against Brucella melitensis infection of sheep.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Brucellosis vaccines: assessment of Brucella melitensis lipopolysaccharide rough mutants defective in core and O-polysaccharide synthesis and export

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Evaluation of Brucella abortus phosphoglucomutase (pgm) mutant as a new live rough-phenotype vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Inactivation of formyltransferase (wbkC) gene generates a Brucella abortus rough strain that is attenuated in macrophages and in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Oral vaccination with Brucella melitensis WR201 protects mice against intranasal challenge with virulent Brucella melitensis 16M.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Evaluation of protection afforded by Brucella abortus and Brucella melitensis unmarked deletion mutants exhibiting different rates of clearance in BALB/c mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Attenuated bioluminescent Brucella melitensis mutants GR019 (virB4), GR024 (galE), and GR026 (BMEI1090-BMEI1091) confer protection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

The Brucella abortus S19 DeltavjbR live vaccine candidate is safer than S19 and confers protection against wild-type challenge in BALB/c mice when delivered in a sustained-release vehicle

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

The Brucella abortus phosphoglycerate kinase mutant is highly attenuated and induces protection superior to that of vaccine strain 19 in immunocompromised and immunocompetent mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

21 January 2018

Brucellosis in Brazil.

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

21 January 2018

Brucellosis in Argentina

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Cyclic β-1,2-glucan is a brucella virulence factor required for intracellular survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Increases of efficacy as vaccine against Brucella abortus infection in mice by simultaneous inoculation with avirulent smooth bvrS/bvrR and rough wbkA mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

Vaccination with Brucella recombinant DnaK and SurA proteins induces protection against Brucella abortus infection in BALB/c mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

The Protein Moiety of Brucella abortus Outer Membrane Protein 16 Is a New Bacterial Pathogen-Associated Molecular Pattern That Activates Dendritic Cells In Vivo, Induces a Th1 Immune Response, and Is a Promising Self-Adjuvanting Vaccine against Syste

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

A DNA vaccine coding for the chimera BLSOmp31 induced a better degree of protection against B. ovis and a similar degree of protection against B. melitensis than Rev.1 vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.110

21 January 2018

Identifiers

DOI

10.1586/ERV.11.110

1 reference

25 August 2017

1 reference